Biopharma · FDA Approvals · Stock

CRDL Cardiol Therapeutics

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibro…

Assets on file: CardiolRx

Start live analysis of CRDL Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for CRDL, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for CRDL, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 23, 2026

06:00 PM

CRDLCardiol Therapeutics

Cardiol Therapeutics expands Phase 3 MAVERIC trial of CardiolRx in recurrent pericarditis

Cardiol achieved its original 110-patient enrollment target in the Phase 3 MAVERIC trial ahead of the end-of-September 2026 guidance. Following a blinded review showing fewer-than-expected recurrences, the Steering Committee recommended expanding enrollment to up to 150 patients to preserve statistical power. Topline results are now guided for mid-2027.

Trial registry changeCompany press release Open record